Processed Residual Pump Blood in Cardiac Surgery: The PRBC Trial
- Conditions
- Cardiopulmonary BypassHemorrhageSurgery
- Interventions
- Other: Ultrafiltration of residual blood
- Registration Number
- NCT01173822
- Lead Sponsor
- Hamilton Health Sciences Corporation
- Brief Summary
The study is an randomized controlled trial (RCT) of 198 coronary artery bypass graft (CABG) patients, exploring whether ultrafiltration of residual blood in the cardiopulmonary bypass circuit reduces transfusion and bleeding.
- Detailed Description
Blood products are a limited resource and cardiac surgery is a high consumer. Processing residual cardiopulmonary bypass (CPB) volume via ultrafiltration may improve hemostasis and reduce transfusion through clearing activated complement, activated coagulation components, and proinflammatory cytokines. Unlike cell saver technology, ultrafiltration has the advantage of maintaining plasma proteins, platelets, and coagulation factors. We sought to establish if the processing of residual CPB volume with ultrafiltration reduces homologous blood transfusion and bleeding.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
- at least 18 years of age
- were to undergo isolated on-pump CABG
- were able to give informed consent
- performed autologous blood donation
- underwent off-pump CABG
- emergency procedure
- resternotomy
- known bleeding disorder not drug related
- history of heparin-induced thrombocytopenia
- Jehovah's Witness
- intra-operative catastrophe prior to randomization
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Treatment group Ultrafiltration of residual blood Ultra filtration of residual blood. Control Ultrafiltration of residual blood The current practice in our institution was to displace all the remaining volume in the CPB circuit into a transfer pack by displacing the remaining blood in the CPB circuit with additional Lactated Ringers solution. This transfer pack is then given to the anesthetist for reinfusion into the patient.
- Primary Outcome Measures
Name Time Method the proportion of patients transfused with homologous red blood cells (RBC) At 30 days post-operatively
- Secondary Outcome Measures
Name Time Method Proportion of patients transfused with any blood product At 30 days post-operatively Volume of pRBC's transfused post-operative At 30 days post-operatively Post-operative hemorrhage At 24 hours post-operative Discharge Hemoglobin A date of discharge, median 5 days in study Length of hospital stay From day to surgery to discharge, median 5 days in this study
Trial Locations
- Locations (1)
Hamilton General Hospital
🇨🇦Hamilton, Ontario, Canada